 |
Funding Opportunites - Research
Further details regarding this announcement can be found at:
http://www.alz.org/professionals_and_researchers_research_programs.asp
|
|
Sponsor/Award: |
ALZHEIMER'S ASSOCIATION - NOVEL PHARMACOLOGICAL STRATEGIES TO PREVENT ALZHEIMER'S - 2010 COMPETITION |
|
|
Grant Amount: |
$400,000 OVER 2 YEARS |
|
Deadline: |
Dean's: Dec 24, 2009
Internal: Dec 31, 2009
Sponsor's: Jan 07, 2010
|
|
|
Subject Areas: |
Alzheimer Disease And Related Dementia, Cognitive Development or Processes, Cognitive Dysfunction, Alzheimer's Disease, Drug Development, Drugs, Drug Safety, Drug Effectiveness, drug screening, novel drug targets, drug efficacy, preclincial study, proof of principle |
|
Description: |
a new initiative to stimulate the development of new pharmacological strategies to prevent or treat Alzheimer's disease. The Association's Request for Applications (RFAs) is aimed at the identification and validation of novel drug targets, the screening and development of drugs for such targets, and the evaluation of drug safety and efficacy, mostly at the preclinical level. The RFA is designed to enable preliminary pilot research or proof-of-principle studies that can provide data for further research support by other funding agencies. Based on discussions with members of its Medical and Scientific Advisory Council, the Association puts forth several themes that may be particularly worthy of further research. Note that ?novel drug target? in the context of this RFA is defined as a drug target that has not yet been published or has not been in the public domain for more than one year and that is clearly different from established drug targets that no longer meet this criterion. Any proposal must have a clear focus on Alzheimer's disease and on a novel drug target as defined above. Any study that uses animal models must clearly and explicitly outline potential methods of translating and relating findings to the human condition in the future. Ultimately, the goal is to translate the research into strategies to delay, halt, reverse or prevent Alzheimer's disease.
Because the principle idea is to encourage studies into new technologies and high-risk ventures and translation of this novel technology to human studies, an interdisciplinary approach might be most fruitful. Therefore, the Association strongly encourages submissions from collaborative research teams (e.g., basic scientists and clinical researchers). In addition, while novel and creative ideas are sought, proposals also need to demonstrate feasibility. |
|
|
Application Details: |
Researchers with full-time staff or faculty appointments are encouraged to apply. Applications from post-doctoral candidates will not be accepted. Each proposal must be submitted to a specific grant competition. In addition, all applicants in every competition are asked to classify their proposals according to four broad categories of scientific inquiry: (1) social and behavioral research, (2) clinical investigations, (3) basic biology and (4) adaptive technology. During second-level review, these categories help the Alzheimer's Association Medical and Scientific Advisory Council ensure a balanced, well-distributed award portfolio.INDIRECT COSTS OF 10% MUST BE INCLUDED IN PROPOSAL BUDGET |
|
NOTE: Letters of Intent and Full Applications are to be processed through Research Development Services for institutional signatures, and are to be accompanied by a completed RDAF form (bearing applicant, Chair and Dean signatures). Requests for Institutional signatures should be received no less than 3 days prior to the posted Sponsor deadline. |
|
Western Contacts: |
Pocock,Katy
Russelo,Theresa M
|
|
|
Sponsor Contacts: |
GRANTSAPP@ALZ.ORG
225 N. Michigan Ave.,
Fl 1700
CHICAGO, Illinois, United States
312 335-5807
|
|